Fig. 3: Results of targeted gene next-generation sequencing, classification, and outcome according to mutation status. | Nature Communications

Fig. 3: Results of targeted gene next-generation sequencing, classification, and outcome according to mutation status.

From: Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Fig. 3

Landscape plot of next generation sequencing results. The genes related to each LymphGen subtype are annotated in the left. There were seven patients whose data on the BCL2, BCL6, and MYC rearrangements were not available, which are marked with dark gray color. Source data are provided as a Source Data file. CR complete remission, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, GCB germinal center B-cell type, NE not evaluable, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease.

Back to article page